Feb 26, 2024 · Bosutinib is used in adults and children at least 1 year old to treat a type of blood cancer called Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) in chronic phase. Bosutinib is also used to treat adults with Ph+ CML in accelerated or blast phase.

Bosutinib, sold under the brand name Bosulif, is a small molecule BCR-ABL and src tyrosine kinase inhibitor used for the treatment of chronic myelogenous leukemia. [2] Originally synthesized by Wyeth, it is being developed by Pfizer. [citation needed]

Apr 1, 2025 · Bosutinib is used to treat chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) in patients who are newly-diagnosed or who have taken other medicines that did not work well.

BOSULIF is part of a group of medicines called tyrosine kinase inhibitors (TKIs). TKIs can block BCR-ABL function, slowing the growth of leukemia cells. For some patients, this allows their white blood cells to return to normal levels. Not taking your …

BOSULIF is indicated for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or...

Bosutinib is an antineoplastic agent used for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adults with inadequate clinical response to other treatments.

BOSULIF is indicated for the treatment of: Adult and pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or intolerant to …

Do not take BOSULIF if you are allergic to bosutinib or any of the ingredients in BOSULIF. See the end of this leaflet for a complete list of ingredients of BOSULIF. Before taking BOSULIF, tell your doctor about all of your medical conditions, including if you: •

Bosutinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells.

Bosutinib is approved to treat: Chronic myelogenous leukemia (CML) that is Philadelphia chromosome positive. It is used: In adults and children aged 1 year and older with chronic phase CML that is newly diagnosed or cannot be treated with or did not respond to other treatment.